Engitix, a British BioTech firm concentrating on the extracellular matrix (ECM) to develop transformative therapies for most cancers and fibrosis, at present introduced the closing of a €21 million ($25 million) Collection A extension financing.
The financing was supplied by Netherton Investments, a fund investing on behalf of Mike Platt, the co-founder and Managing Director of BlueCrest Capital Administration.
“Closing this financing strengthens our skill to translate Engitix’s distinctive ECM understanding right into a rising pipeline of focused therapeutics,” mentioned Giuseppe Mazza, CEO and co-founder of Engitix. “Our platform and dataset place us to speed up preclinical growth throughout oncology and fibrosis applications and construct differentiated, ECM-targeted therapeutics with the potential to meaningfully enhance affected person outcomes.”
Within the European BioTech and drug-development sector, 2025 noticed continued capital deployment throughout oncology, fibrosis and adjoining therapeutic areas, inserting Engitix’s €21 million Collection A extension inside a broader sample of mid- to late-stage funding exercise.
Comparable rounds embrace TargED Biopharmaceuticals within the Netherlands, which secured €21.5 million to advance focused thrombotic illness therapies, carefully mirroring Engitix in each stage and funding measurement. Bigger oncology-focused raises have been reported for FoRx Therapeutics in Switzerland (€42 million for DNA-repair most cancers therapies), Adcytherix in France (€105 million for novel antibody-drug conjugates), and Tubulis in Germany (€308 million to develop its ADC pipeline).
The UK has additionally remained energetic, with Trogenix elevating €80 million to speed up most cancers remedies and Scripta Therapeutics securing over €10 million for its drug-discovery platform, making Engitix a part of a cluster of British BioTech financings this 12 months.
Extra exercise consists of Italy-based NanoPhoria (€83.5 million for a heart-failure remedy) and Eire’s Aerska (€17 million for RNAi medicines concentrating on mind ailments).
Taken collectively, these rounds account for nicely over €600 million in disclosed BioTech funding in 2025, indicating sustained investor curiosity in therapeutics platforms.
Based in 2016, Engitix is a BioTech firm creating therapies that concentrate on the extracellular matrix (ECM) to deal with most cancers and fibrosis. By integrating large-scale ECM datasets with translational biology and drug growth, Engitix goals to construct a pipeline of differentiated therapeutics designed to behave inside illness tissue microenvironments.
The corporate has a strategic drug discovery partnership with Dompé farmaceutici and growth collaborations with Takeda in superior fibrotic liver ailments.
Mike Platt, Investor Director, added: “Engitix has developed a compelling technique on the intersection of knowledge, biology, and drug growth. I’m happy to proceed supporting Engitix because it advances its programmes in fibrosis and stable tumours.”
The brand new proceeds might be used to proceed preclinical growth throughout Engitix’s proprietary ECM-targeted pipeline in stable tumours and fibrosis, and to additional develop and apply Engitix’s platform constructed on one of many largest proprietary ECM datasets in these ailments.
